Trials / Completed
CompletedNCT01173120
Methotrexate - Inadequate Response Device Sub-Study
Sub-study-A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and acceptability of a device used in place of traditional syringes for abatacept self-injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Abatacept combination product (ACP) | Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-02-01
- Completion
- 2010-07-01
- First posted
- 2010-07-30
- Last updated
- 2012-01-12
- Results posted
- 2011-07-06
Source: ClinicalTrials.gov record NCT01173120. Inclusion in this directory is not an endorsement.